139 related articles for article (PubMed ID: 34795129)
1. Occurrence of Infusion-Related Reactions due to Obinutuzumab Therapy for Follicular Lymphoma.
Azuma K; Matsuo K; Nemoto M; Uekusa S; Yokoyama M; Terui Y; Hama T; Yoshio T
Gan To Kagaku Ryoho; 2021 Nov; 48(11):1369-1373. PubMed ID: 34795129
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Greil R; Tedeschi A; Moreno C; Anz B; Larratt L; Simkovic M; Gill D; Gribben JG; Flinn IW; Wang Z; Cheung LWK; Nguyen AN; Zhou C; Styles L; Demirkan F
Ann Hematol; 2021 Jul; 100(7):1733-1742. PubMed ID: 34018029
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
Dhillon S
Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
[TBL] [Abstract][Full Text] [Related]
6. Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
Dawson K; Moran M; Guindon K; Wan H
Clin J Oncol Nurs; 2016 Apr; 20(2):E41-8. PubMed ID: 26991722
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Radford J; Davies A; Cartron G; Morschhauser F; Salles G; Marcus R; Wenger M; Lei G; Wassner-Fritsch E; Vitolo U
Blood; 2013 Aug; 122(7):1137-43. PubMed ID: 23843495
[TBL] [Abstract][Full Text] [Related]
8. Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial.
Xing S; Pu Y; Zhao X; Hu Y; Zhang F; Gu Z; Xu W; Fan L; Miao Y; Li J
Braz J Med Biol Res; 2024; 57():e13284. PubMed ID: 38359273
[TBL] [Abstract][Full Text] [Related]
9. Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.
Hara T; Suzuki R; Ohno A; Yamakawa K; Yamagishi Y; Sugiyama Y; Sobajima T; Yamada R; Matsumoto R; Ikeda Y; Murayama M; Tsurumi H
Int J Hematol; 2020 Apr; 111(4):585-590. PubMed ID: 31848991
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
Morschhauser FA; Cartron G; Thieblemont C; Solal-Céligny P; Haioun C; Bouabdallah R; Feugier P; Bouabdallah K; Asikanius E; Lei G; Wenger M; Wassner-Fritsch E; Salles GA
J Clin Oncol; 2013 Aug; 31(23):2912-9. PubMed ID: 23835718
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
15. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia.
Pejsa V; Lucijanic M; Vrkljan Vuk A; Stoos-Veic T; Jaksic O; Jonjic Z; Pirsic M; Prka Z; Ivic M; Fazlic Dzankic A; Mitrovic Z
Leuk Lymphoma; 2020 Apr; 61(4):934-939. PubMed ID: 31842643
[TBL] [Abstract][Full Text] [Related]
16. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
Jean GW; Comeau JM
Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
18. [Modified Premedication of Infusion Reaction with Obinutuzumab Therapy].
Sakamoto R; Mukai J; Kotake Y; Takehara R; Nishimura M; Yamada K; Okuda H; Wada Y
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1073-1076. PubMed ID: 38035837
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Sharman JP; Forero-Torres A; Costa LJ; Flinn IW; Inhorn L; Kelly K; Bessudo A; Fayad LE; Kaminski MS; Evens AM; Flowers CR; Sahin D; Mundt KE; Sandmann T; Fingerle-Rowson G; Vignal C; Mobasher M; Zelenetz AD
Leuk Lymphoma; 2019 Apr; 60(4):894-903. PubMed ID: 30277102
[TBL] [Abstract][Full Text] [Related]
20. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]